Sign in

International Journal of Neuropsychopharmacology

@ijnp.bsky.social
79 followers 244 following 98 posts

The official journal of The International College of Neuropsychopharmacology (CINP) linktr.ee/ijnp

PostsRepliesMedia
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 3h
📢 Call for Papers: Mitochondria, Mind & Medicines Working in #mitochondrial biology, stress research, neuroscience, psychobiology, or #metabolicpsychiatry? We invite you to contribute! 🔗 Explore the topic academic.oup.com/ijnp/pages/c... #Neuropsychopharmacology #Psychiatry #Bioenergetics
000
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026
A recent exploratory study investigated whether the degree of antidepressant treatment resistance influences ketamine's therapeutic effects in patients with TRD. 📖 Read the article: doi.org/10.1093/ijnp...
doi.org
Distinct therapeutic profiles of ketamine in treatment-resistant depression: an exploratory analysis
AbstractObjective. Intravenous ketamine demonstrates rapid efficacy for treatment-resistant depression (TRD). However, its impact on individual depressive
000
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026
Does psychostimulant treatment improve cognitive and motor performance in adults with ADHD? A recent study compared adults with medicated ADHD, unmedicated ADHD, and healthy controls across a comprehensive battery of motor and cognitive tests.
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026
🔍 How can we ensure AI is safe, transparent, and accountable in psychiatry? A recent perspective in IJNP argues that responsible AI in psychiatry requires more than ethical principles. It needs practical governance frameworks that can be implemented and evaluated.
doi.org
Responsible artificial intelligence integration framework for psychiatric guidelines
Abstract. Artificial intelligence (AI) is reshaping medicine, promising advances in diagnosis, monitoring, and treatment, and psychiatry will be no excepti
110
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026
🧠 Can EEG help predict who responds to cariprazine? A recent study by Bitter et al. found that treatment responders showed increased theta and decreased delta resting-state EEG power. Importantly, baseline gamma activity predicted treatment response with high accuracy..
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 18/06/2026
We're delighted to share that IJNP has achieved an increased Impact Factor. Strong readership and usage show that IJNP research is being discovered and used worldwide. Consider IJNP for your next paper: academic.oup.com/ijnp
000
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 30/05/2026
Are you attending the CINP World Congress? We invite you to visit the IJNP booth and join our dedicated sessions to meet the Editors. Connect with our editorial team, discuss your research ideas, explore future publishing opportunities! #CINP2026 #neuropsychopharmacology
010
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 30/05/2026
Are you attending the CINP World Congress? We invite you to visit the IJNP booth and join our dedicated sessions to meet the Editors. Connect with our editorial team, discuss your research ideas, explore future publishing opportunities! #CINP2026 #neuropsychopharmacology
000
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 13/05/2026
Can existing medicines unlock new treatments for mental health? The International Journal of Neuropsychopharmacology IJNP is excited to announce a new Call for Papers for our upcoming special collection: Drug Repurposing in Psychiatry ijnp.net/rp @wegener.bsky.social @liveagodoy.bsky.social
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 26/04/2026
Psychopharmacology is being reshaped by drug repurposing, and it challenges current classification systems #ibogaine We moved from indication-based to mechanism-based classification. But does that fully capture the new psychotropic landscape? A recent IJNP paper proposes a complementary distinction
120
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 15/03/2026
Can sweet taste preference predict response to naltrexone in alcohol use disorder (AUD)? A recent study published in IJNP evaluated whether the sweet-liking phenotype is associated with response to naltrexone treatment in Taiwanese patients with AUD.
111
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 20/02/2026
🧠Novel Targets for the Treatment of Schizophrenia: Moving Beyond Dopamine While dopamine blockade remains central to antipsychotic treatment, major unmet needs persist, particularly for negative, cognitive symptoms. Check the collection for more info: academic.oup.com/ijnp/pages/s...
doi.org
Efficacy and Safety of the Muscarinic Receptor Agonist KarXT (Xanomeline-Trospium) in Schizophrenia: A Systematic Review, Meta-Analysis and Bayesian Sensitivity Analysis
AbstractBackground. Schizophrenia significantly impacts global health, with existing treatments primarily focusing on positive symptoms and often causing c
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 06/02/2026
🧠 Neurostimulation is redefining long-term treatment in psychiatry Vagus nerve stimulation (VNS) & sustained benefit in depression 📄 A recent paper published in IJNP reports robust long-term outcomes with VNS in MDD! 📊 Impressive findings:
doi.org
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report
Significance Statement Patients with markedly treatment-resistant major depression have a low likelihood of benefiting from antidepressant treatments and a
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 23/01/2026
💊 Preclinical pharmacology with implications for AUD drug development This study reports the preclinical evaluation of MC-100093, a novel compound that reduces voluntary ethanol intake in both male and female rats, supporting its potential as a pharmacological lead for alcohol use disorder.
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 10/01/2026
The Orexin System: Understanding the Modern Insomnia Treatment By pharmacologically targeting dual orexin receptor antagonists (DORAs), this class of agents promotes sleep through a fundamentally different mechanism DORAs ⬇️ the "wake drive" rather than inducing widespread neuronal inhibition
doi.org
Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant
Abstract. Insomnia is a serious public health concern. As the widely prescribed hypnotics that positively modulate gamma-aminobutyric acid (GABA)A receptor
110
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 22/12/2025
As the year draws to a close, we wish you and your loved ones a very Happy Holiday season and a peaceful, healthy, and productive New Year. We look forward to the continued collaboration of the IJNP community in 2026. On behalf of the IJNP Editorial Management Group
010
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 19/12/2025
Dopamine's link to positive affect isn't linear—it could be U-shaped🧠 The recently published paper in IJNP shows that an individual's trait positive affectivity critically moderates how dopamine modulation influences state positive affect. In a double-blind design:
110
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 27/11/2025
Connect with the international community of neuropsychopharmacology! Follow us across our Social Media Platforms. linktr.ee/ijnp
010
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 21/11/2025
Editor’s Pick of the month! This month’s featured paper delivers important insights for the large group of patients with major depressive disorder who achieve only limited improvement on standard antidepressants.
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 14/11/2025
Opioid and Ketamine in the clinic: key methodological considerations The question of whether ketamine’s antidepressant effects are mediated by glutamatergic plasticity or opioid receptor signalling remains a subject of considerable debate.
110
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 07/11/2025
🧠 Do dopamine D₂ partial agonists all bind the same way? Maybe not. New evidence challenges the idea that all “third-generation” antipsychotics share a single D₂ receptor binding mode. #Neuropsychopharmacology #Antipsychotics #Dopamine
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 27/10/2025
🧠 Hyperprolactinemia is usually seen as a side effect of antipsychotics — but could it be part of schizophrenia itself? In first-episode, non- to minimally treated patients, there was a clear sex-specific endocrine disturbance.
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 24/10/2025
🧠 Brain–Body in Postoperative Cognitive Dysfunction (POCD) POCD is a common issue in older adults after surgery, causing memory loss + slower thinking But what if the gut has something to do with it? 🦠 IJNP paper highlights how the gut–brain axis shapes recovery after surgery. #GutBrainAxis
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 17/10/2025
Duloxetine for Depression, how it is effectively targeting NET? This is the first study to use PET imaging to track long-term NET occupancy, providing evidence on the SNRI mechanism without the influence of other medications.
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 10/10/2025
In this month’s Editor’s Pick, Hashimoto et al. deliver an insightful meta-analysis comparing personality profiles in schizophrenia & bipolar disorder.
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/10/2025
💊Lithium vs. Other Mood Stabilizers: Distinct Metabolic Signatures in #Bipolar Disorder (BP) BD is primarily treated with mood stabilizers (MS): lithium represents the gold standard. Despite its high clinical efficacy, the molecular players in treatment response remain partly unclear👇 #MedEd
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 26/09/2025
New Study Alert: Anhedonia in MDD - Clinical Correlates & Treatment Response🧠 🚨New research published in IJNP confirms anhedonia (MADRS item 8 – inability to feel) as a key marker for severe MDD course.
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 23/09/2025
🚨Call for Symposia – CINP 2026, Glasgow🚨 Be part of shaping the scientific programme at one of Europe’s most vibrant cities!🌍✨ 📅Deadline: 7th October 2025 💡30 symposia slots available – don’t miss this chance! cinp2026.org/submissions/... #cinp #neuropsychopharmacology
cinp2026.org
Symposium Submission - Glasgow CINP2026
Symposia shall be of 75 minutes duration, and shall include three speakers, one of whom can, if desired, be the chairperson of the session.
000
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 19/09/2025
📣Join CINP + BJPsych joint journal club to discuss the future of academic psychiatry with Prof Allan Young and experts!
000
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 19/09/2025
🧠🤖Affective states as clinical signals: AI models for decision-making and symptoms This month’s Editor’s Pick examines the role of affective states in computational psychiatry—a field that uses mathematical and AI-based models to link behavior, brain function, and mental health.
220
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 10/09/2025
📢Exciting news #CINP2026 in Glasgow will be a Joint Meeting of the Scandinavian College of Neuropsychopharmacology +the International College of Neuropsychopharmacology! Join us for this unique event which promises to be an outstanding meeting of science &collaboration @actaneuropsych.bsky.social
020
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 05/09/2025
🧠🍷Neurogenesis, Ethanol & biomarker It is known that excessive ethanol disrupts hippocampal structure/function, especially with adolescent onset. But how does neurogenesis plays out in this context?
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 29/08/2025
⚡Beyond the Powerhouse: Mitochondria, Genes, and Depression in a Cross-Species Study 🧠🔋When mitochondrial function falters, the brain struggles to meet energy demands, contributing to the impaired plasticity observed in MDD. #Mitochondria #Depression
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 29/08/2025
We are delighted to announce that the abstracts from CINP-AsCNP 2025 Joint Congress in Melbourne have been published as a Supplement to the International Journal of Neuropsychopharmacology Read the abstracts here: academic.oup.com/ijnp/issue/2...
academic.oup.com
Volume 28 Issue Supplement_2 | International Journal of Neuropsychopharmacology | Oxford Academic
The official journal of Collegium Internationale Neuro-Psychopharmacologicum. Publishes papers that advance understanding of existing and new neuropsychopharmacological agents or provide insights into...
010
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 26/08/2025
Is it possible to predict antidepressant response? 📌 Check the Editor’s July Pick in #IJNP This recent study investigated whether brain activity patterns (EEG) could help predict which patients with depression may respond to antidepressants (#vortioxetine or #escitalopram).
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 15/08/2025
🔬 Personality Traits in Schizophrenia vs. Bipolar Disorder Personality traits play pivotal roles in the onset, manifestation, and progression of schizophrenia (SCZ) and bipolar disorder (BD).
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 08/08/2025
🧠 More Than Mood: Anhedonia as a Public Health & Economic Issue How one symptom can ripple through mental health, productivity, and the healthcare system. In a large US study of ~75,000 adults (≥18 years) with depression, higher anhedonia was tied to:
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 01/08/2025
🧠 Over 100 types of RNA modifications exist, but N6-methyladenosine (m6A) is the most prevalent. How are the modifications on neurotransmitters, plasticity and other mechanisms related to #Depression #Autism #Schizophrenia?
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 22/07/2025
🌍World Brain Day | 22 July - Brain Health for All Ages 🧠 As a journal dedicated to advancing neuropsychopharmacology, we join the global neuroscience community in recognizing World Brain Day Understanding brain function in both health and disease is central to improving lives
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 04/07/2025
📢IJNP is pleased to welcome the new EiC, @wegener.bsky.social IJNP continues to publish high-impact original articles, reviews, perspectives, and guidelines in basic and clinical neuropsychopharmacology.
110
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 01/07/2025
📢 IJNP is pleased to welcome the new Editor-in-Chief, Prof. Gregers Wegener On behalf of the CINP Executive Committee and the new editorial team, we extend our sincere gratitude to Prof Anthony Grace and the editorial board for their outstanding leadership and dedication over the years
100
International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/06/2025
📢 We’re now on Social Media! 🧠🌐 The International Journal of Neuropsychopharmacology is expanding its presence across your favourite platforms. Follow us to stay up to date with: Cutting-edge research Trending articles Educational content Calls for papers and special issue alerts 🔗 linktr.ee/ijnp
010